Correlation of CRP/Albumin ratio and low serum albumin with the risk of major adverse cardiovascular events in elderly patients with chronic total occlusion

CRP/白蛋白比值和低血清白蛋白与老年慢性完全闭塞患者发生主要不良心血管事件风险的相关性

阅读:2

Abstract

OBJECTIVE: The C-reactive protein (CRP)/albumin (ALB) ratio (CAR), a key marker of inflammation and nutrition is closely associated with the risk of cardiovascular events. CAR’s potential to predict major adverse cardiovascular events (MACE) in elderly individuals with chronic total occlusion (CTO) has not been evaluated. Therefore, the aim of this study was to elucidate the correlation between CAR and the risk of MACE in elderly patients with CTO. METHODS: This prospective cohort study consecutively included 134 patients with CTO. ALB and CRP concentrations were measured after patient admission, and CAR was calculated. Patients were followed up by telephone for a median period of 12 months and categorized into a MACE group (41 patients) and a no-MACE group (93 patients) according to the occurrence of MACE during the follow-up period. The relationship between CAR and the risk of MACE was analyzed by COX regression, and the performance of ALB, CRP, and CAR in predicting the risk of MACE was assessed using ROC curve. Kaplan-Meier survival curves were used to analyze patient survival, with subgroup analysis based on CAR. RESULTS: The incidence of MACE in 134 CTO patients was 30.60%. ALB (HR, 0.693; 95% CI, 0.588–0.861; P = 0.001) and CAR (HR, 1.128; 95% CI, 1.050–1.212; P = 0.001) were shown to be independent predictors of MACE in patients with CTO. The AUC for CAR was 0.807, surpassing the AUCs of CRP at 0.766 and ALB at 0.700 individually. The ROC curve indicated that the optimal value to distinguish between MACE and no-MACE groups was 0.1210. Patients with CAR ≥ 0.1210 and ALB < 35.86 g/L had a significantly higher risk of MACE over 2 years (P < 0.001). Final subgroup analysis showed no significant interaction between CAR and each subgroup (interaction P: 0.056–0.859). CONCLUSION: CAR independently predicts MACE in CTO patients and provides superior prognostic value compared to using CRP or ALB alone.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。